JRMS 22
Alternative Names: JRMS-22Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Neuropeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action TDP-43 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Frontotemporal dementia; Huntington's disease; Parkinson's disease
Most Recent Events
- 27 Jan 2025 Neuropeutics enters into collaboration with LifeArc to develop JRMS 22 for treatment of Amyotrophic Lateral Sclerosis
- 27 Jan 2025 Preclinical trials in Alzheimer's disease in Canada (unspecified route) before 2025
- 27 Jan 2025 Preclinical trials in Amyotrophic lateral sclerosis in Canada (unspecified route) before 2025